
Opinion|Videos|October 14, 2024
Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy
Key Takeaways
- Route of administration impacts patient compliance and convenience, influencing the choice of PD-1/PD-L1 agents.
- Duration of therapy affects patients' quality of life and is a key consideration in treatment selection.
Panelists discuss how various factors, such as route of administration, duration of therapy, safety, efficacy, and cost, could influence the selection of different PD-1/PD-L1 agents once they receive approval, highlighting the importance of these considerations in optimizing patient care.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What factors could influence the choice between different PD-1/PD-L1 agents if they are eventually approved [ie, route of administration, duration of therapy, safety, efficacy, place of administration, drug preservation, biomarkers, cost, etc]?
Advertisement
Related to this article

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.

This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.

The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.

Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.

Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Casdatifan shows activity across treatment settings in advanced ccRCC
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5



